University of Zaragoza, Teruel, Spain.
Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain.
Health Qual Life Outcomes. 2018 Mar 12;16(1):46. doi: 10.1186/s12955-018-0866-2.
Emotional disorders, which include both anxiety and depressive disorders, are the most prevalent psychological disorders according to recent epidemiological studies. Consequently, public costs associated with their treatment have become a matter of concern for public health systems, which face long waiting lists. Because of their high prevalence in the population, finding an effective treatment for emotional disorders has become a key goal of today's clinical psychology. The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders might serve the aforementioned purpose, as it can be applied to a variety of disorders simultaneously and it can be easily performed in a group format.
The study is a multicenter, randomized, non-inferiority controlled clinical trial. Participants will be 220 individuals with emotional disorders, who are randomized to either a treatment as usual (individual cognitive behavioral therapy) or to a Unified Protocol condition in group format. Depression, anxiety, and diagnostic criteria are the primary outcome measures. Secondary measures include the assessment of positive and negative affect, anxiety control, personality traits, overall adjustment, and quality of life. An analysis of treatment satisfaction is also conducted. Assessment points include baseline, post-treatment, and three follow-ups at 3, 6, and 12 months. To control for missing data and possible biases, intention-to-treat and per-protocol analyses will be performed.
This is the first randomized, controlled clinical trial to test the effectiveness of a transdiagnostic intervention in a group format for the treatment of emotional disorders in public settings in Spain. Results obtained from this study may have important clinical, social, and economic implications for public mental health settings in Spain.
Retrospectively registered at https://clinicaltrials.gov/ . Trial NCT03064477 (March 10, 2017). The trial is active and recruitment is ongoing. Recruitment is expected to finish by January 2020.
根据最近的流行病学研究,情绪障碍(包括焦虑症和抑郁症)是最常见的心理障碍。因此,与治疗相关的公共成本已成为公共卫生系统关注的问题,因为这些系统面临着很长的候诊名单。由于它们在人群中的高患病率,寻找一种有效的情绪障碍治疗方法已成为当今临床心理学的主要目标。情绪障碍的跨诊断统一治疗方案可能符合上述目的,因为它可以同时应用于多种障碍,并且可以很容易地以小组形式进行。
该研究是一项多中心、随机、非劣效性对照临床试验。参与者将是 220 名患有情绪障碍的个体,他们将被随机分配到常规治疗(个体认知行为疗法)或小组形式的统一方案条件。抑郁、焦虑和诊断标准是主要的结局测量指标。次要指标包括积极和消极情绪的评估、焦虑控制、人格特质、整体适应和生活质量。还进行了治疗满意度的分析。评估点包括基线、治疗后和 3、6 和 12 个月的 3 次随访。为了控制缺失数据和可能的偏差,将进行意向治疗和方案治疗分析。
这是第一项在西班牙公共环境中以小组形式对跨诊断干预进行随机对照临床试验,以测试其治疗情绪障碍的有效性。这项研究的结果可能对西班牙公共精神卫生机构具有重要的临床、社会和经济意义。
在 https://clinicaltrials.gov/ 进行了回顾性注册。试验 NCT03064477(2017 年 3 月 10 日)。试验正在进行中,正在招募参与者。预计招募将于 2020 年 1 月完成。